Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06596473
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-11
Brief Title:
A Study of BG-C477 in Participants With Advanced Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multicenter Open-Label Phase 1ab First-in-Human Study to Investigate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety tolerability pharmacokinetics pharmacodynamics and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors
Detailed Description:
This new study will check how safe and helpful a potential anticancer drug called BG-C477 is This drug will be tested by itself or combined with other anticancer agents The purpose of this study is to test if BG-C477 is safe and if it works in people with your disease when it is given on its own and in combination with other anticancer agents
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None